Skip to main content
Erschienen in: CardioVascular and Interventional Radiology 9/2023

25.07.2023 | Laboratory Investigation

Infigratinib, a Selective Fibroblast Growth Factor Receptor Inhibitor, Suppresses Stent-Induced Tissue Hyperplasia in a Rat Esophageal Model

verfasst von: Yan Fu, He Zhao, Jingui Li, Yawei Li, Tao Gong, Chao An, Ruosu Wang, Xiao Li

Erschienen in: CardioVascular and Interventional Radiology | Ausgabe 9/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Stent-induced tissue hyperplasia remains a challenge for the application of self-expanding metal stents in the management of esophageal stricture. This study aimed to evaluate the efficacy of infigratinib, which is a selective fibroblast growth factor receptor inhibitor, in the prevention of stent-induced tissue hyperplasia in a rat esophageal model.

Methods

Twenty-four male Sprague–Dawley rats underwent esophageal stent placement and were randomized to receive 1 ml of vehicle, 5 mg/kg infigratinib in 1 ml of vehicle, or 10 mg/kg infigratinib in 1 ml of vehicle via naso-gastric tube once daily for 28 days. Follow-up fluoroscopy was performed on postoperative day 28, and the stented esophageal tissues were harvested for histological and immunofluorescence examinations.

Results

All rats survived until euthanasia on postoperative day 28 without procedure-related adverse events. The incidence of stent migration was 12.5%, 12.5% and 25% in the control group, the 5 mg/kg infigratinib group and, the 10 mg/kg infigratinib group, respectively. The percentage of granulation tissue area, the submucosal fibrosis thickness, the number of epithelial layers, the degree of inflammatory cell infiltration, the degree of collagen deposition, the number of fibroblast growth factor receptor 1 (FGFR1)-expressing myofibroblasts, and the number of proliferating myofibroblasts were all significantly lower in both infigratinib groups than in the control group (P < 0.05) but were not significantly different between the two infigratinib groups (P > 0.05).

Conclusions

Infigratinib significantly suppresses stent-induced tissue hyperplasia by inhibiting FGFR1-mediated myofibroblast proliferation and profibrotic activities in a rat esophageal model.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Bakken JC, Wong Kee Song LM, de Groen PC, Baron TH. Use of a fully covered self-expandable metal stent for the treatment of benign esophageal diseases. Gastrointest Endosc. 2010;72(4):712–20.CrossRefPubMed Bakken JC, Wong Kee Song LM, de Groen PC, Baron TH. Use of a fully covered self-expandable metal stent for the treatment of benign esophageal diseases. Gastrointest Endosc. 2010;72(4):712–20.CrossRefPubMed
2.
Zurück zum Zitat Chan MQ, Balasubramanian G, Modi RM, et al. Changing epidemiology of esophageal stent placement for dysphagia: a decade of trends and the impact of benign indications. Gastrointest Endosc. 2020;92(1):56-64.e57.CrossRefPubMed Chan MQ, Balasubramanian G, Modi RM, et al. Changing epidemiology of esophageal stent placement for dysphagia: a decade of trends and the impact of benign indications. Gastrointest Endosc. 2020;92(1):56-64.e57.CrossRefPubMed
3.
Zurück zum Zitat Felix NS, de Mendonça L, Braga CL, et al. Effects of the FGF receptor-1 inhibitor, infigratinib, with or without sildenafil, in experimental pulmonary arterial hypertension. Br J Pharmacol. 2019;176(23):4462–73.CrossRefPubMedPubMedCentral Felix NS, de Mendonça L, Braga CL, et al. Effects of the FGF receptor-1 inhibitor, infigratinib, with or without sildenafil, in experimental pulmonary arterial hypertension. Br J Pharmacol. 2019;176(23):4462–73.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Fuccio L, Hassan C, Frazzoni L, Miglio R, Repici A. Clinical outcomes following stent placement in refractory benign esophageal stricture: a systematic review and meta-analysis. Endoscopy. 2016;48(2):141–8.PubMed Fuccio L, Hassan C, Frazzoni L, Miglio R, Repici A. Clinical outcomes following stent placement in refractory benign esophageal stricture: a systematic review and meta-analysis. Endoscopy. 2016;48(2):141–8.PubMed
5.
Zurück zum Zitat Gkolfakis P, Siersema PD, Tziatzios G, Triantafyllou K, Papanikolaou IS. Biodegradable esophageal stents for the treatment of refractory benign esophageal strictures. Ann Gastroenterol. 2020;33(4):330–7.PubMedPubMedCentral Gkolfakis P, Siersema PD, Tziatzios G, Triantafyllou K, Papanikolaou IS. Biodegradable esophageal stents for the treatment of refractory benign esophageal strictures. Ann Gastroenterol. 2020;33(4):330–7.PubMedPubMedCentral
6.
Zurück zum Zitat Guagnano V, Furet P, Spanka C, et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6- [4-(4-ethyl-piperazin-1-yl)-phenylamin o]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem. 2011;54(20):7066–83.CrossRefPubMed Guagnano V, Furet P, Spanka C, et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6- [4-(4-ethyl-piperazin-1-yl)-phenylamin o]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem. 2011;54(20):7066–83.CrossRefPubMed
7.
Zurück zum Zitat Hirdes MM, Siersema PD, van Boeckel PG, Vleggaar FP. Single and sequential biodegradable stent placement for refractory benign esophageal strictures: a prospective follow-up study. Endoscopy. 2012;44(7):649–54.CrossRefPubMed Hirdes MM, Siersema PD, van Boeckel PG, Vleggaar FP. Single and sequential biodegradable stent placement for refractory benign esophageal strictures: a prospective follow-up study. Endoscopy. 2012;44(7):649–54.CrossRefPubMed
8.
Zurück zum Zitat Imaz-Iglesia I, García-Pérez S, Nachtnebel A, et al. Biodegradable stents for the treatment of refractory or recurrent benign esophageal stenosis. Expert Rev Med Devices. 2016;13(6):583–99.CrossRefPubMed Imaz-Iglesia I, García-Pérez S, Nachtnebel A, et al. Biodegradable stents for the treatment of refractory or recurrent benign esophageal stenosis. Expert Rev Med Devices. 2016;13(6):583–99.CrossRefPubMed
9.
Zurück zum Zitat Inoue Y, King TE Jr, Barker E, Daniloff E, Newman LS. Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2002;166(5):765–73.CrossRefPubMed Inoue Y, King TE Jr, Barker E, Daniloff E, Newman LS. Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2002;166(5):765–73.CrossRefPubMed
10.
Zurück zum Zitat Javle M, Lowery M, Shroff RT, et al. Phase II study of BGJ398 in patients With FGFR-altered advanced cholangiocarcinoma. J Clin Oncol. 2018;36(3):276–82.CrossRefPubMed Javle M, Lowery M, Shroff RT, et al. Phase II study of BGJ398 in patients With FGFR-altered advanced cholangiocarcinoma. J Clin Oncol. 2018;36(3):276–82.CrossRefPubMed
11.
Zurück zum Zitat Jun EJ, Park JH, Tsauo J, et al. EW-7197, an activin-like kinase 5 inhibitor, suppresses granulation tissue after stent placement in rat esophagus. Gastrointest Endosc. 2017;86(1):219–28.CrossRefPubMed Jun EJ, Park JH, Tsauo J, et al. EW-7197, an activin-like kinase 5 inhibitor, suppresses granulation tissue after stent placement in rat esophagus. Gastrointest Endosc. 2017;86(1):219–28.CrossRefPubMed
12.
Zurück zum Zitat Jun EJ, Song HY, Park JH, et al. In Vivo fluorescence microendoscopic monitoring of stent-induced fibroblast cell proliferation in an esophageal mouse model. J Vasc Interv Radiol. 2018;29(12):1756–63.CrossRefPubMed Jun EJ, Song HY, Park JH, et al. In Vivo fluorescence microendoscopic monitoring of stent-induced fibroblast cell proliferation in an esophageal mouse model. J Vasc Interv Radiol. 2018;29(12):1756–63.CrossRefPubMed
14.
Zurück zum Zitat Karakan T, Utku OG, Dorukoz O, et al. Biodegradable stents for caustic esophageal strictures: a new therapeutic approach. Dis Esophagus. 2013;26(3):319–22.CrossRefPubMed Karakan T, Utku OG, Dorukoz O, et al. Biodegradable stents for caustic esophageal strictures: a new therapeutic approach. Dis Esophagus. 2013;26(3):319–22.CrossRefPubMed
15.
Zurück zum Zitat Katoh M. Therapeutics targeting FGF signaling network in human diseases. Trends Pharmacol Sci. 2016;37(12):1081–96.CrossRefPubMed Katoh M. Therapeutics targeting FGF signaling network in human diseases. Trends Pharmacol Sci. 2016;37(12):1081–96.CrossRefPubMed
16.
Zurück zum Zitat Kim EY, Shin JH, Jung YY, Shin DH, Song HY. A rat esophageal model to investigate stent-induced tissue hyperplasia. J Vasc Interv Radiol. 2010;21(8):1287–91.CrossRefPubMed Kim EY, Shin JH, Jung YY, Shin DH, Song HY. A rat esophageal model to investigate stent-induced tissue hyperplasia. J Vasc Interv Radiol. 2010;21(8):1287–91.CrossRefPubMed
17.
Zurück zum Zitat Kim EY, Shin JH, Song HY, et al. Suppression of stent-induced tissue hyperplasia in rats by using small interfering RNA to target matrix metalloproteinase-9. Endoscopy. 2014;46(6):507–12.CrossRefPubMed Kim EY, Shin JH, Song HY, et al. Suppression of stent-induced tissue hyperplasia in rats by using small interfering RNA to target matrix metalloproteinase-9. Endoscopy. 2014;46(6):507–12.CrossRefPubMed
18.
Zurück zum Zitat Kochhar R, Samanta J, Basha J, et al. biodegradable stents for caustic esophageal strictures: do they work? Dysphagia. 2017;32(4):575–82.CrossRefPubMed Kochhar R, Samanta J, Basha J, et al. biodegradable stents for caustic esophageal strictures: do they work? Dysphagia. 2017;32(4):575–82.CrossRefPubMed
19.
Zurück zum Zitat Lawrance IC, Rogler G, Bamias G, et al. Cellular and molecular mediators of intestinal fibrosis. J Crohns Colitis. 2017;11(12):1491–503.PubMed Lawrance IC, Rogler G, Bamias G, et al. Cellular and molecular mediators of intestinal fibrosis. J Crohns Colitis. 2017;11(12):1491–503.PubMed
20.
Zurück zum Zitat Morizumi S, Sato S, Koyama K, et al. Blockade of pan-fibroblast growth factor receptors mediates bidirectional effects in lung fibrosis. Am J Respir Cell Mol Biol. 2020;63(3):317–26.CrossRefPubMed Morizumi S, Sato S, Koyama K, et al. Blockade of pan-fibroblast growth factor receptors mediates bidirectional effects in lung fibrosis. Am J Respir Cell Mol Biol. 2020;63(3):317–26.CrossRefPubMed
21.
Zurück zum Zitat Nonaka K, Miyazawa M, Ban S, et al. Different healing process of esophageal large mucosal defects by endoscopic mucosal dissection between with and without steroid injection in an animal model. BMC Gastroenterol. 2013;13:72.CrossRefPubMedPubMedCentral Nonaka K, Miyazawa M, Ban S, et al. Different healing process of esophageal large mucosal defects by endoscopic mucosal dissection between with and without steroid injection in an animal model. BMC Gastroenterol. 2013;13:72.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Rijcken E, Sachs L, Fuchs T, Spiegel HU, Neumann PA. Growth factors and gastrointestinal anastomotic healing. J Surg Res. 2014;187(1):202–10.CrossRefPubMed Rijcken E, Sachs L, Fuchs T, Spiegel HU, Neumann PA. Growth factors and gastrointestinal anastomotic healing. J Surg Res. 2014;187(1):202–10.CrossRefPubMed
23.
Zurück zum Zitat Song HY, Jung HY, Park SI, et al. Covered retrievable expandable nitinol stents in patients with benign esophageal strictures: initial experience. Radiology. 2000;217(2):551–7.CrossRefPubMed Song HY, Jung HY, Park SI, et al. Covered retrievable expandable nitinol stents in patients with benign esophageal strictures: initial experience. Radiology. 2000;217(2):551–7.CrossRefPubMed
24.
Zurück zum Zitat Spaander MC, Baron TH, Siersema PD, et al. Esophageal stenting for benign and malignant disease: European Society of gastrointestinal endoscopy (ESGE) clinical guideline. Endoscopy. 2016;48(10):939–48.CrossRefPubMed Spaander MC, Baron TH, Siersema PD, et al. Esophageal stenting for benign and malignant disease: European Society of gastrointestinal endoscopy (ESGE) clinical guideline. Endoscopy. 2016;48(10):939–48.CrossRefPubMed
25.
Zurück zum Zitat Spaander MCW, van der Bogt RD, Baron TH, et al. Esophageal stenting for benign and malignant disease: European society of gastrointestinal endoscopy (ESGE) Guideline - Update 2021. Endoscopy. 2021;53(7):751–62.CrossRefPubMed Spaander MCW, van der Bogt RD, Baron TH, et al. Esophageal stenting for benign and malignant disease: European society of gastrointestinal endoscopy (ESGE) Guideline - Update 2021. Endoscopy. 2021;53(7):751–62.CrossRefPubMed
26.
Zurück zum Zitat Sun WL, Zhu YP, Ni XS, et al. Potential involvement of Fgf10/Fgfr2 and androgen receptor (AR) in renal fibrosis in adult male rat offspring subjected to prenatal exposure to di-n-butyl phthalate (DBP). Toxicol Lett. 2018;282:37–42.CrossRefPubMed Sun WL, Zhu YP, Ni XS, et al. Potential involvement of Fgf10/Fgfr2 and androgen receptor (AR) in renal fibrosis in adult male rat offspring subjected to prenatal exposure to di-n-butyl phthalate (DBP). Toxicol Lett. 2018;282:37–42.CrossRefPubMed
27.
Zurück zum Zitat Türkyilmaz Z, Sönmez K, Karabulut R, et al. Mitomycin C decreases the rate of stricture formation in caustic esophageal burns in rats. Surgery. 2009;145(2):219–25.CrossRefPubMed Türkyilmaz Z, Sönmez K, Karabulut R, et al. Mitomycin C decreases the rate of stricture formation in caustic esophageal burns in rats. Surgery. 2009;145(2):219–25.CrossRefPubMed
28.
Zurück zum Zitat Wick G, Grundtman C, Mayerl C, et al. The immunology of fibrosis. Annu Rev Immunol. 2013;31:107–35.CrossRefPubMed Wick G, Grundtman C, Mayerl C, et al. The immunology of fibrosis. Annu Rev Immunol. 2013;31:107–35.CrossRefPubMed
29.
Zurück zum Zitat Ye LP, Zheng HH, Mao XL, Zhang Y, Zhou XB, Zhu LH. Complete circular endoscopic resection using submucosal tunnel technique combined with esophageal stent placement for circumferential superficial esophageal lesions. Surg Endosc. 2016;30(3):1078–85.CrossRefPubMed Ye LP, Zheng HH, Mao XL, Zhang Y, Zhou XB, Zhu LH. Complete circular endoscopic resection using submucosal tunnel technique combined with esophageal stent placement for circumferential superficial esophageal lesions. Surg Endosc. 2016;30(3):1078–85.CrossRefPubMed
30.
Zurück zum Zitat Zhang S, Ye F, Sun L. Use of stent for prevention of esophageal stricture after circumferential endoscopic submucosal dissection. Dig Endosc Off J Jpn Gastroenterol Endosc Soc. 2019;31(Suppl 1):21. Zhang S, Ye F, Sun L. Use of stent for prevention of esophageal stricture after circumferential endoscopic submucosal dissection. Dig Endosc Off J Jpn Gastroenterol Endosc Soc. 2019;31(Suppl 1):21.
31.
Zurück zum Zitat Zhao H, Zhao L, Zhou Z, Wu Y. The roles of connective tissue growth factor in the development of anastomotic esophageal strictures. Arch Med Sci. 2015;11(4):770–8.CrossRefPubMedPubMedCentral Zhao H, Zhao L, Zhou Z, Wu Y. The roles of connective tissue growth factor in the development of anastomotic esophageal strictures. Arch Med Sci. 2015;11(4):770–8.CrossRefPubMedPubMedCentral
Metadaten
Titel
Infigratinib, a Selective Fibroblast Growth Factor Receptor Inhibitor, Suppresses Stent-Induced Tissue Hyperplasia in a Rat Esophageal Model
verfasst von
Yan Fu
He Zhao
Jingui Li
Yawei Li
Tao Gong
Chao An
Ruosu Wang
Xiao Li
Publikationsdatum
25.07.2023
Verlag
Springer US
Erschienen in
CardioVascular and Interventional Radiology / Ausgabe 9/2023
Print ISSN: 0174-1551
Elektronische ISSN: 1432-086X
DOI
https://doi.org/10.1007/s00270-023-03502-1

Weitere Artikel der Ausgabe 9/2023

CardioVascular and Interventional Radiology 9/2023 Zur Ausgabe

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärztinnen und Psychotherapeuten.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.